S-1: Bolt Projects Holdings Faces Delisting Amid Share Resale

Bolt Projects Holdings filed an S-1 for the resale of up to 913,979 common shares by existing stockholders, while facing Nasdaq delisting and significant financial losses.

Summary

• The company is registering up to 913,979 shares of common stock for resale by Selling Stockholders, comprising 518,817 initial shares and up to 395,162 shares from pre-funded warrants.
• The company will not receive any proceeds from the sale of shares by the Selling Stockholders.
• Bolt Projects Holdings' common stock is listed on Nasdaq under the symbol BSLK, with a closing price of $8.90 per share on August 21, 2025.
• The company is classified as an emerging growth company and a smaller reporting company, benefiting from reduced public company reporting requirements.
• It reported a net loss of $65.4 million for the year ended December 31, 2024, and $10.5 million for the six months ended June 30, 2025.
• As of June 30, 2025, the accumulated deficit stood at $472.3 million.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• The company received a Nasdaq delisting notice on August 12, 2025, due to non-compliance with minimum Market Value of Listed Securities ($50 million) and Market Value of Publicly Held Shares ($15 million) requirements; a hearing is scheduled for September 16, 2025.
• Since early 2023, the company has strategically focused 100% on its Vegan Silk Technology Platform (b-silk and xl-silk), discontinuing other product candidates like Mylo.
• The August 2025 PIPE Transaction generated approximately $4.25 million in gross proceeds for the company.
• An agreement with Southern Point Capital (Seneca Transaction) involves purchasing up to $1.7 million of outstanding vendor payables, convertible into common stock.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including substantial doubt about its ability to continue as a going concern, an imminent Nasdaq delisting threat, and a history of significant net losses and accumulated deficit. While there is some revenue growth in the core product and efforts to raise capital, these are overshadowed by the existential risks. The stock option repricing and the August 2025 PIPE transaction at a price significantly below the recent closing price further indicate a distressed valuation. The overall risk profile is extremely high.

Positives

• Revenue from the Vegan Silk Technology Platform increased by 2,225% to $1.302 million for Q2 2025 compared to $0.056 million in Q2 2024, and by 1,864% to $1.473 million for H1 2025 compared to $0.075 million in H1 2024.
• Gross income improved from a loss of $0.03 million in Q2 2024 to a gain of $0.06 million in Q2 2025, and from a loss of $0.08 million in H1 2024 to a gain of $0.06 million in H1 2025, driven by reduced material costs and pricing discipline.
• The August 2025 PIPE Transaction successfully raised approximately $4.25 million in gross proceeds for the company.
• The Vegan Silk Technology Platform, including b-silk and xl-silk, is fully biodegradable, film-forming, versatile, and functional, supported by 80 granted patents and 116 pending patent applications.
• Laurus Bio, the primary manufacturing partner, is expanding capacity with a third facility expected by H2 2026, and the company is validating a second supplier and evaluating a third to diversify manufacturing.
• b-silk products have been commercially available in consumer formulations since 2019, with substantial manufacturing cost reductions achieved through process optimization.
• Management has initiated remediation efforts for internal control weaknesses, including hiring key finance roles (VP Finance, Controller) and engaging consultants.

Negatives

• The company reported a net loss of $65.4 million for the year ended December 31, 2024, and $10.5 million for the six months ended June 30, 2025.
• An accumulated deficit of $472.3 million as of June 30, 2025, indicates significant historical losses.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months, with cash and cash equivalents of $1.0 million as of June 30, 2025, deemed insufficient for future operating needs.
• The company received a Nasdaq delisting notice on August 12, 2025, for failing to meet minimum Market Value of Listed Securities ($50 million) and Market Value of Publicly Held Shares ($15 million) requirements.
• Negative net working capital of $5.5 million as of June 30, 2025.
• High dependency on the success of the Vegan Silk Technology Platform, which currently has limited product and brand recognition.
• Reliance on a single manufacturing partner (Laurus Bio) and facility creates supply chain risks.
• Revenue decreased by 60% ($2.1 million) for the year ended December 31, 2024, compared to 2023, partly due to a major customer not making purchases in 2024 after significant orders in 2023.
• Identified material weaknesses in internal control over financial reporting as of December 31, 2024.
• Incurred a $26.4 million loss on extinguishment of convertible notes in 2024.
• Incurred $19.3 million in property and equipment impairment and $2.3 million in lease impairment in 2023 due to discontinuing Mylo production and suspending R&D operations.
• An excise tax payable of $2.9 million as of June 30, 2025, is accruing penalties and interest due to non-payment by the October 31, 2024 deadline.
• The company does not intend to pay dividends for the foreseeable future.
• The resale of shares by Selling Stockholders could negatively impact the market for common stock, increasing volatility, limiting market activity, or causing a price decline.

Risks

• History of losses and negative cash flows from operations raises substantial doubt about the ability to continue as a going concern.
• Inability to generate sufficient cash to service debt obligations may force the company to reduce investments, sell assets, or seek additional capital, which may not be successful.
• Inability to achieve or maintain profitability in the future due to limited commercial operations and operating in a rapidly evolving industry.
• Risk of delisting from Nasdaq if the appeal is unsuccessful, which would adversely affect market liquidity and ability to raise capital.
• Significant future expenses and capital expenditures are expected to execute the business plan, with potential inability to control expenses or raise additional capital on favorable terms.
• High dependency on the success of the Vegan Silk Technology Platform, which has limited product and brand recognition.
• Future biomaterial product candidates may not achieve market success, leading to insufficient revenue generation.
• Reliance on a single manufacturing partner and facility for production, with risks of disruption from regulatory noncompliance, natural disasters, supply chain issues, or geopolitical factors.
• A limited number of customers, distributors, and collaboration partners account for a material portion of revenue, and their loss could harm operating results.
• Certain contracts granting exclusivity rights to customers may limit the ability to sell products in specific markets.
• Substantial competition from incumbent materials (silicone elastomers) and other new entrants, risking failure to gain or loss of market share.
• Identified material weaknesses in internal control over financial reporting, which could lead to inaccurate financial reporting and adversely affect investor confidence.
• Inability to adequately protect patents and other intellectual property assets, potentially affecting competitive position and product value, with costly litigation risks.
• Reliance on trade secrets to protect technology, with risks if trade secret protection is not obtained or maintained.
• Third parties may claim infringement of their intellectual property rights, leading to substantial litigation expense, damages, or licensing costs.
• Inability to manage rapid growth effectively could have a material adverse effect on business, results of operations, and financial condition.
• Pricing and availability of products may be impacted by factors outside of control, including end market demand, manufacturing costs, and raw material supply.
• Inability to secure required quantities of third-party raw materials could prevent fulfillment of customer demand.
• Increased production costs could necessitate raising prices, negatively impacting customer acquisition and retention.
• Financial results could vary materially from quarter to quarter due to various factors, making accurate forecasting difficult.
• Dependence on key personnel; inability to attract and retain skilled individuals could adversely affect the business.
• Management's limited experience in operating a public company could divert attention from day-to-day business.
• An increase in shipping and freight costs may not be fully passed through to customers, negatively impacting profitability.
• Attention to sustainability matters may impact business, financial results, and operating model, including potential 'greenwashing' allegations.
• Heightened operational and cybersecurity risks as a remote-first company.
• Government regulations and private party actions relating to marketing and advertising of cosmetic products may restrict sales and harm the business.
• Products not manufactured in compliance with legal requirements or resulting in adverse health effects could lead to reputational harm, remedial costs, or governmental enforcement.
• Changes in government regulation may require modification of operations or product formulations.
• Failure to comply with laws relating to the privacy, security, and processing of Personal Information could result in legal claims, fines, or reputational damage.
• Global economic and financial market conditions, including downturns, could impact demand in key customer end-markets and the ability to obtain financing.
• The market price of common stock has been and may be volatile, leading to potential loss of investment.
• Future acquisitions or investments may divert management's attention, result in dilution, or expose the company to unknown risks or liabilities.
• Future litigation or similar legal proceedings could have a material adverse effect on business and results of operations.
• Anti-takeover provisions in the certificate of incorporation could adversely affect the rights of stockholders.
• Forum selection provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Reduced public company reporting requirements as an emerging growth company and smaller reporting company may make securities less attractive to investors.

Future Outlook

The company expects to incur significant losses and negative cash flows for at least the next few years as it works to expand market share and commercialize its products. It is committed to developing the Vegan Silk Technology Platform as a foundation for a high-value, scalable business with attractive costs and margins, which is expected to enable future reinvestment and expansion into additional sustainable materials. Cost of goods optimization is anticipated to accelerate with economies of scale as product volume grows. The long-term goal is to become a leader in synthetic biomaterials, with plans to introduce new vegan silk products and production strains to offer lower cost options. To fund operations, the company expects to generate additional customer contracts and restructure current equity instruments and financial obligations. The manufacturing partner, Laurus Bio, is undergoing capacity expansion, projected to add substantial capacity by the second half of 2026, and the company plans to validate multiple alternative manufacturing sources to enhance supply chain resilience.

Management Comments

• "Our aspiration is to transform the global consumer goods industry, starting in beauty and personal care with ingredients that are better for the environment while improving product performance. In short: way better materials, for a way better world."
• "By discontinuing the development of all other product candidates, and concentrating our resources and expertise, we are accelerating the commercialization of biotechnology ingredients for the beauty and personal care industry, unlocking new applications and long-term value for our investors, partners, and customers."
• "Moving forward, we are committed to developing the Vegan Silk Technology Platform as our foundation for a high-value, scalable business with attractive costs and margins."
• "We believe this would enable us to reinvest in our broader portfolio, expanding our Vegan Silk Technology Platform to include additional sustainable materials that support our mission of building biomaterial platforms for high-volume consumer goods brands."
• "We believe our product claims are truthful, not misleading, and would not cause our products to be regulated as drugs."
• "We believe our ability to compete successfully in designing, engineering, and manufacturing our products at significantly reduced cost to customers does and will depend on a number of factors..."
• "We believe that utilizing a third-party manufacturing partner enables us to focus on our core competencies and maintain a capital efficient business model while leveraging this third partys state of the art facilities, up-to-date and certified compliance with regulatory entities and economies of scale."
• "We believe formulators consistent focus on cost efficiencies will encourage expansion of the use of these products."
• "The Companys executive officers and directors have studied and fully understand the nature of the transaction contemplated by this Agreement and recognize that they have a potential dilutive effect. The board of directors of the Company has concluded in its good faith business judgment that such transaction is in the best interests of the Company."

Industry Context

The beauty and personal care market, which Bolt Projects Holdings serves, is projected to grow at a 7.7% compound annual rate to reach $973 billion by 2030. This growth is driven by a shift towards sustainable solutions and away from synthetic materials. The global silicone market within this sector is valued between $16.7 billion and $19.9 billion, with silicone elastomers alone representing a $6.3 billion to $10.0 billion market, growing at a 6% CAGR. Environmental concerns regarding silicone elastomers are creating demand for alternatives. Bolt Projects Holdings faces competition from traditional silicone producers and other biomaterial developers like Givaudan Active Beauty (Silkgel), Spiber Inc. (Brewed Protein), Seevix Material Sciences (SVX), and Evolved by Nature (Activated Silk). However, the filing notes that none of these competitors are currently marketed as direct silicone elastomer alternatives, potentially positioning Bolt uniquely in this niche.

Comparison to Industry Standards

• The Vegan Silk Technology Platform products are designed to substantially replace silicone elastomers, aiming to match or outperform them on key attributes and provide additional active benefits.
• Products like b-silk are fully biodegradable and non-toxic, offering a sustainable alternative to problematic, bio-persistent silicone elastomers.
• Vegan Silk Technology Platform products are efficacious at lower loading levels compared to silicone elastomers, which can help formulators reduce their costs of goods while maintaining product performance.
• While competitors like Givaudan Active Beauty (Silkgel), Spiber Inc. (Brewed Protein), Seevix Material Sciences (SVX), and Evolved by Nature (Activated Silk) exist in the biomaterials space, none are currently marketed as direct alternatives to silicone elastomers, suggesting a differentiated market position for Bolt Projects Holdings.

Management Changes

Corporate Governance

Legal Proceedings

• Donoghue v. Golden Arrow Sponsor, LLC: A lawsuit filed on June 29, 2025, in the United States District Court for the Southern District of New York, asserting claims under Section 16(b) of the Securities Exchange Act of 1934 against Golden Arrow Sponsor, LLC. The company is named as a nominal defendant and is not accused of wrongdoing.

Related Party Transactions

• **Settlement Agreement and Exchange Agreement (February 14, 2025)**: Entered with Golden Arrow Sponsor, LLC (the Sponsor). The Sponsor is obligated to use commercially reasonable efforts to provide or organize $10 million in financing by August 13, 2025, and contribute 75% of excise tax payments (capped at the amount received from selling 50% of its common stock). The company exchanged 250,000 Private Placement Warrants held by the Sponsor for 250,000 Sponsor Warrants at an exercise price of $10.00 per share.
• **Amended and Restated Registration Rights and Lock-up Agreement (August 13, 2024)**: Entered with the Sponsor, former GAMC directors and officers, Bolt Threads directors and officers, and certain Bolt Threads stockholders, granting registration rights and imposing transfer restrictions on Lock-Up Shares (which ended February 14, 2025).
• **Sponsor Subscription Agreement (October 4, 2023)**: The Sponsor originally committed to purchase 40,000 shares of GAMC Class A common stock for $8.0 million. This agreement was amended in February and June 2024, reducing the Sponsor's commitment as it purchased $10 million in Convertible Notes instead, thus not being obligated to purchase PIPE Shares.
• **Note Purchase Agreement (October 4, 2023)**: Entered with PIPE Subscribers, including the Sponsor and entities affiliated with Foundation Capital, Top Tier, and Jerry Fiddler. This agreement led to the issuance of Convertible Notes totaling $29.6 million (including $2.0 million to three related parties) and Bridge Warrants.
• **Ginkgo Note Purchase Agreement (October 2022, amended December 2023 and April 2024)**: Ginkgo Bioworks, Inc. holds Senior Secured Notes. The December 2023 amendment involved exchanging $10.0 million principal for a convertible note, $11.8 million for an Amended Senior Note, a nonexclusive IP license, and a $5.4 million reduction in the prepaid balance for the 2022 Technical Development Agreement. The April 2024 amendment allowed for capitalization of interest payments and required a $0.5 million prepayment post-Merger. Ginkgo is a related party.
• **Securities Purchase Agreement (November 25, 2024)**: Entered with Daniel Widmaier (CEO), David Breslauer (CTO), Randy Befumo (Interim CFO), Jeri Finard (Director), and an entity affiliated with Jerry Fiddler (Director). The company sold 52,941 shares of common stock for $360,000 at $6.80 per share.
• **Technical Development Agreement (2022 TDA)**: An agreement with Ginkgo Bioworks, Inc. (a related party) under which the company made a $10.0 million upfront payment for future technical services. A remaining credit of $3.0 million was available as of June 30, 2025.
• **Founder Shares**: The Sponsor holds 352,375 Founder Shares, which are subject to specific transfer restrictions.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from current and future equity raises (PIPE, Seneca, warrants). The threat of Nasdaq delisting could severely impact the liquidity and market price of their shares. Anti-takeover provisions in the corporate governance structure limit shareholder influence on major corporate decisions.
• **Employees**: Executive compensation includes significant stock-based components. The company implemented a workforce reduction in 2023. As a remote-first company, employees are subject to heightened operational and cybersecurity risks.
• **Customers**: Benefit from the company's sustainable biomaterial alternatives to silicone elastomers. However, reliance on a single manufacturing partner poses a risk of supply chain disruptions. Exclusivity contracts with certain customers may limit product availability in other markets.
• **Suppliers**: The Seneca Transaction involves the potential acquisition of outstanding vendor payables. The company's reliance on a single manufacturing partner (Laurus Bio) and its capacity expansion plans are critical for supply chain stability.
• **Creditors**: The company has substantial debt obligations (e.g., Senior Secured Notes) and faces challenges in generating sufficient cash to service them, leading to substantial doubt about its going concern status. Debt covenants impose restrictions on the company's operations.
• **Regulatory Bodies**: The company is subject to SEC reporting requirements, Nasdaq listing rules (currently non-compliant), FDA regulations for cosmetic products, FTC advertising rules, and data privacy laws. Non-compliance could lead to enforcement actions, fines, and reputational damage.

Next Steps

• Attend the Nasdaq Hearings Panel on September 16, 2025, to appeal the delisting determination and present a compliance plan.
• Continue efforts to remediate identified material weaknesses in internal control over financial reporting.
• Increase sales of Vegan Silk Technology Platform products to existing and new customers.
• Expand fermentation capacity with current and future manufacturing partners.
• Continue research and development to optimize b-silk, xl-silk, and future biomaterial products, including developing lower-cost options.
• Diversify and strengthen the manufacturing network by validating a second supplier and evaluating a third.
• Obtain additional capital through equity offerings, debt financing, or restructuring current obligations to fund operations.
• Continue making estimated monthly payments of $0.04 million to the IRS for the excise tax liability.
• Potentially issue shares to Southern Point Capital Corporation (Seneca) upon court order for vendor payable settlement.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by substantial doubt about its ability to continue as a going concern, a significant accumulated deficit of $472.3 million, and insufficient cash to fund operations for the next 12 months. The imminent threat of Nasdaq delisting, despite an appeal, poses a severe risk to liquidity and investor confidence. While recent capital raises and some revenue growth in its core product are noted, these are insufficient to offset the fundamental financial instability and high operational risks, including reliance on a single manufacturer and customer concentration. The recent PIPE transaction at $4.65 per share, significantly below the market price, indicates a distressed valuation. Given these severe and immediate challenges, the stock carries an extremely high risk profile, making it an unfavorable investment.

Keywords

Biomaterials, Vegan Silk Technology Platform, b-silk, xl-silk, Sustainable materials, Beauty and personal care, Silicone elastomers replacement, SEC S-1 filing, Nasdaq delisting, Going concern, Capital raise, Biotechnology, Intellectual property, Manufacturing partner, Financial losses, Risk factors, Corporate governance, Emerging growth company, Smaller reporting company